Latest News and Press Releases
Want to stay updated on the latest news?
-
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data...
-
SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class...
-
Jade Biosciences Outlines Key 2026 Objectives and Strategy
-
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on...
-
Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its...
-
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on...
-
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class...
-
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
-
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
-
Jade Biosciences Announces $135 Million Private Placement